Tamsulosin test

Preclinical

AADIUM

Tamsulosin test is one of 4 therapeutic programs targeting Bioequivalance. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

BioequivalanceCompleted

BioequivalancePreclinical

Completed

Competition

Competitive Landscape

3 competitors in Bioequivalance

#DrugCompanyPhaseTrials

Test

RRespirent Pharmaceuticals Co Ltd.

Preclinical

3 2

Reference

RRespirent Pharmaceuticals Co Ltd.

Preclinical

3 3

Janumet XR

AADIUM

Preclinical

3 4

Tamsulosin test

AADIUM

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bioequivalance1 trial

Clinical Study to Determine Bioequivalence Between Two Oral Tamsulosin Products as 0.4 mg Prolonged-release Tablets in Healthy Male Subjects Under Fasted Conditions

Completed·AADIUM·Preclinical·NCT07698275·34 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tamsulosin test. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Tamsulosin test. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — ADIUM company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: AADIUM

Tamsulosin test

Status by Indication[2][1]

Competitive Landscape

Trials by Indication[1]

Bioequivalance1 trial

References

Drug Info

Quick Facts

Related News